Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Blood Cancer J. 2016 May 6;6(5):e418. doi: 10.1038/bcj.2016.27.

Z Chen^{1

2}, W Wang¹, J E Cortes³, E Liu⁴, R N Miranda¹, C Zhao⁵, J Yuan⁶, X Lu¹, W Yang¹, M D Ameri⁷, H M Kantarjian³, L J Medeiros¹, S Hu¹

¹ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
³ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Pathology, Institute of Hematology & Blood Diseases Hospital, Tianjin, China.
⁵ Department of Pathology, University of Iowa, Iowa City, IA, USA.
⁶ Department of Pathology, University of Nebraska, Omaha, NE, USA.
⁷ Department of Pathology, City of Hope National Medical Center, Duarte, CA, USA.

No abstract available

Publication types